In addition, galectin-1 is involved cancer progression, enhances the migration and invasion of human GBM cells [6, 7] and angiogenesis [8], inhibits the anti-tumor immunity of natural killer (NK) cells [30–32], is involved in glioma chemoresistance [33], and may be considered a biomarker because serum galectin-1 levels are higher in patients with high-grade glioma than in healthy controls [10]. The gene discussed is LGALS1; the disease is cancer.